OpusPoint Partners, LLC is an investment advisory firm specializing in healthcare and life sciences.[1]
 | |
| Company type | Private Equity Investment Firm |
|---|---|
| Industry | Private equity |
| Founded | 2009 |
| Headquarters | New York, NY, United States |
Key people | Michael S. Weiss, Lindsay A. Rosenwald |
| Products | Venture capital, Consulting |
| Website | OpusPoint |
Background
editFounded in 2009 by Michael S. Weiss and Lindsay A. Rosenwald, MD,[2] the firm acts as the investment manager for some portfolio private hedge funds in the healthcare and biotechnology sectors.[3]
In October 2010, OpusPoint invested approximately $3 million into National Holdings Corporation and formed a joint venture. As a result, a new investment banking firm, OPN Capital Markets, was established to leverage the resources of both companies.[4][5]
Among others, OpusPoint Partners participated in the private placement for such companies as Sunesis Pharmaceuticals, Inc. that developed Voreloxin, an anticancer drug used in acute myeloid leukemia.[6]
References
edit- ^ "National Holdings Corporation Completes Equity Financing Led By OpusPoint Partners; Parties To Enter Into Strategic Alliance". reuters.com. 6 Oct 2010. Retrieved 2011-06-13.
- ^ "OpusPoint Partners History". opuspointpartners.com. Retrieved 2011-06-13.
- ^ "SECURITIES AND EXCHANGE COMMISSION (FORM 8-K)". markets.on.nytimes.com. 2011. Retrieved 2011-06-13.
- ^ "National Holdings Corporation Completes Equity Financing Led By OpusPoint Partners; Parties To Enter Into Strategic Alliance". reuters.com. 6 Oct 2010. Retrieved 2011-06-13.
- ^ "National Holdings Completes Equity Financing Led by OpusPoint Partners". DailyFinance.com. 6 Oct 2010. Retrieved 2011-06-13.
- ^ "Sunesis Closes $28.5 Million Final Tranche of 2009 Private Placement". finance.yahoo.com. June 30, 2010. Retrieved 2011-06-13.
External links
edit